This book focuses on innovative treatment options for breast cancer, including surgery, radiotherapy, systemic therapy and of course immunotherapy that is changing outcomes in some aggressive breast cancer histotypes. Subsequent chapters also address the ongoing emerging research in the screening, diagnostics, and management of all subtypes of breast cancers. All current landscapes and future perspectives in each molecular subtype: luminal, HER2-positive, and triple-negative breast cancers are discussed within the different chapters.
Breast cancer is still the most common cancer and cause of cancer deaths among women worldwide. The improvement of breast cancer outcome appears to be strictly related to the validation of precise biomarkers that enable us to better select personalized approaches in breast cancer management.
The closing chapters deal with the challenges of conducting research in the era of precision medicine forcancer. The book is edited and authored by leading experts in this field and will be of interest for clinicians and scientists alike.
Dr. Ouissam Al Jarroudi, MD, is a distinguished medical oncologist practicing in the medical oncology department at Mohammed VI University Hospital in Oujda, Morocco. She holds a position as a professor at the Faculty of Medicine and Pharmacy, affiliated with Mohammed Ist University. Dr. Al Jarroudi has pursued various fellowships at renowned institutions such as the Department of Medical Oncology at Paul Brousse Hospital, Assistance Publique - Hopitaux de Paris, and Léon Bérard Center in France.
Dr. Al Jarroudi's research is primarily focused on prognostic and predictive biomarkers in breast cancer and she is currently a member of the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO).
Khalid El Bairi is a clinical research fellow and an investigator in OVANORDEST studies. He is currently pursuing clinical and translational research in medical oncology. He has published many peer-reviewedarticles in the field of predictive and prognostic cancer biomarkers to improve survival outcomes in several WoS and Medline-indexed journals. His research focuses particularly on biomarkers for digestive and gynecological cancers such as ovarian and colorectal malignancies. He is currently a member of various international scientific societies such as the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the European Society of Gynaecological Oncology (ESGO), and the American Association for Cancer Research (AACR). He is also an editor and reviewer for various journals and a guest editor for several special issues on emerging topics in gynecological cancers such as platinum-resistant ovarian cancer. He is also highly interested in teaching evidence-based medicine, clinical research methods, and publishing ethics to medical and PhD students and was selected for the 70th Lindau Nobel Laureate Meeting as a young scientist. He is also involved in "global oncology" initiatives through providing free training to young researchers across LMICs. He joined the ASCO Trainee & Early Career Advisory Group as a member for the 2022-2024 term and NCODA (National Community Oncology Dispensing Association, Inc.) as an advisory member of its International Executive Council in 2023.
Giuseppe Curigliano, MD PhD, is Associate Professor of Medical Oncology at the University of Milano and the Head of the Division of Early Drug Development at the European Institute of Oncology, IRCCS, Italy. He is a clinician and researcher specializing in early drug development for patients with solid tumors with a special commitment to breast cancer. He has been a member of the Italian National Health Council since 2018 and, in 2019, he served as Chair of the Scientific Committee of The Lega Nazionale Lotta ai Tumori. He has served as a Member of the ESMO Breast Cancer Faculty since 2001 and he is currently the Faculty Coordinator. He has alsoserved on the Scientific Committee for the St Gallen Conference since 2011 and was the Scientific Co-Chair in St Gallen 2017 and 2019. He has been an Editorial Board Member for Annals of Oncology since 2014, and serves as Co-Editor in Chief of The Breast, Co-Editor in Chief of Cancer Treatment Reviews, Associate Editor of the European Journal of Cancer, Editor of the Journal of Clinical Oncology. He also serves on the European School of Oncology (ESO) faculty committee.
